Review



human hepatoma hepg2  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC human hepatoma hepg2
    Human Hepatoma Hepg2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 31385 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human hepatoma hepg2/product/ATCC
    Average 99 stars, based on 31385 article reviews
    human hepatoma hepg2 - by Bioz Stars, 2026-03
    99/100 stars

    Images



    Similar Products

    99
    ATCC human hepatoma hepg2
    Human Hepatoma Hepg2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human hepatoma hepg2/product/ATCC
    Average 99 stars, based on 1 article reviews
    human hepatoma hepg2 - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    99
    ATCC hepg2 human hepatoma cell line
    PPA-mediated reduction in lipid accumulation involves enhanced lipolysis and fatty acid oxidation in <t>HepG2</t> cells. ( A ) Following 24 h incubation with 500 μM oleic acid (OA) or bovine serum albumin (BSA), HepG2 cells were exposed to PPA at concentrations of 0, 0.5, 0.75, 1, or 5 mM for an additional 48 h. Cell viability was determined via the CCK-8 assay. ( B ) Oil Red O staining images illustrate lipid droplets (scale bar = 200 μm). ( C ) Quantitative assessment of lipid content from Oil Red O staining. ( D ) Fluorescence images of BODIPY 493/503-stained lipid droplets (scale bar = 25 μm). ( E ) Mean fluorescence intensity quantification of BODIPY 493/503 staining. ( F , G ) Western blot analysis for detecting phosphorylated ATGL (p-ATGL) and total ATGL (t-ATGL). ( H , I ) CPT1A expression levels were examined by Western blotting. Colors represent the following groups: control (gray), OA alone (green), OA plus PPA at the indicated concentrations (orange). Group labels are displayed on the x-axis. Data represent mean ± SEM; n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns represents no significant difference.
    Hepg2 Human Hepatoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hepg2 human hepatoma cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    hepg2 human hepatoma cell line - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    99
    ATCC hepg2 human hepatoma cells
    ( A ) Top, the results of ChIP-seq with anti-FoxO1 antibody in livers of unfed mice obtained from ChIP-Atlas (ID: GSM3381273); bottom, simplified representation of the structure of the full fragment, fragment 1, fragment 2, fragment 3, and the subdivisions of fragment 1 i.e. small fragment 1A and small fragment 1B. ( B and C ) Enhancer analysis of FoxO1 and FoxO3a on Ass1 enhancer and its fragments. FoxO1 and FoxO3a expression plasmids were co-transfected with the indicated Ass1 enhancer firefly luciferase reporter plasmids in <t>HepG2</t> cells. ( D and E ) Electrophoretic mobility shift assay (EMSA) using radiolabeled probe for ( D ) the two JASPAR predicted FoxO binding sites (Figure S5) in the smallest fragment 1A from the Ass1 enhancer and FoxO binding site in the promoter of Pck1 as a positive control; ( E ) the wild-type (WT) and mutant (Mut) predicted FoxO binding site1 incubated with GST and GST-FoxO recombinant proteins. BS, binding site; WT, wild-type; Mut, mutant. ( F ) Enhancer analysis of FoxO1 and FoxO3a on mutant Ass1 enhancer and its fragments. FoxO1 and FoxO3a expression plasmids were co-transfected with the indicated Ass1 enhancer firefly luciferase reporter plasmids in HepG2 cells. All values are presented as the mean with error bars representing the SEM. Datasets were assessed by Student’s t -test for unpaired samples. The differences were considered to be significant if P < 0.05 (* P < 0.05 and ** P <0.01).
    Hepg2 Human Hepatoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hepg2 human hepatoma cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    hepg2 human hepatoma cells - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    99
    ATCC human hepatoma cell lines hepg2 2 15
    ( A ) Top, the results of ChIP-seq with anti-FoxO1 antibody in livers of unfed mice obtained from ChIP-Atlas (ID: GSM3381273); bottom, simplified representation of the structure of the full fragment, fragment 1, fragment 2, fragment 3, and the subdivisions of fragment 1 i.e. small fragment 1A and small fragment 1B. ( B and C ) Enhancer analysis of FoxO1 and FoxO3a on Ass1 enhancer and its fragments. FoxO1 and FoxO3a expression plasmids were co-transfected with the indicated Ass1 enhancer firefly luciferase reporter plasmids in <t>HepG2</t> cells. ( D and E ) Electrophoretic mobility shift assay (EMSA) using radiolabeled probe for ( D ) the two JASPAR predicted FoxO binding sites (Figure S5) in the smallest fragment 1A from the Ass1 enhancer and FoxO binding site in the promoter of Pck1 as a positive control; ( E ) the wild-type (WT) and mutant (Mut) predicted FoxO binding site1 incubated with GST and GST-FoxO recombinant proteins. BS, binding site; WT, wild-type; Mut, mutant. ( F ) Enhancer analysis of FoxO1 and FoxO3a on mutant Ass1 enhancer and its fragments. FoxO1 and FoxO3a expression plasmids were co-transfected with the indicated Ass1 enhancer firefly luciferase reporter plasmids in HepG2 cells. All values are presented as the mean with error bars representing the SEM. Datasets were assessed by Student’s t -test for unpaired samples. The differences were considered to be significant if P < 0.05 (* P < 0.05 and ** P <0.01).
    Human Hepatoma Cell Lines Hepg2 2 15, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human hepatoma cell lines hepg2 2 15/product/ATCC
    Average 99 stars, based on 1 article reviews
    human hepatoma cell lines hepg2 2 15 - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    99
    ATCC human hepatoma derived cell line hepg2
    ( A ) Top, the results of ChIP-seq with anti-FoxO1 antibody in livers of unfed mice obtained from ChIP-Atlas (ID: GSM3381273); bottom, simplified representation of the structure of the full fragment, fragment 1, fragment 2, fragment 3, and the subdivisions of fragment 1 i.e. small fragment 1A and small fragment 1B. ( B and C ) Enhancer analysis of FoxO1 and FoxO3a on Ass1 enhancer and its fragments. FoxO1 and FoxO3a expression plasmids were co-transfected with the indicated Ass1 enhancer firefly luciferase reporter plasmids in <t>HepG2</t> cells. ( D and E ) Electrophoretic mobility shift assay (EMSA) using radiolabeled probe for ( D ) the two JASPAR predicted FoxO binding sites (Figure S5) in the smallest fragment 1A from the Ass1 enhancer and FoxO binding site in the promoter of Pck1 as a positive control; ( E ) the wild-type (WT) and mutant (Mut) predicted FoxO binding site1 incubated with GST and GST-FoxO recombinant proteins. BS, binding site; WT, wild-type; Mut, mutant. ( F ) Enhancer analysis of FoxO1 and FoxO3a on mutant Ass1 enhancer and its fragments. FoxO1 and FoxO3a expression plasmids were co-transfected with the indicated Ass1 enhancer firefly luciferase reporter plasmids in HepG2 cells. All values are presented as the mean with error bars representing the SEM. Datasets were assessed by Student’s t -test for unpaired samples. The differences were considered to be significant if P < 0.05 (* P < 0.05 and ** P <0.01).
    Human Hepatoma Derived Cell Line Hepg2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human hepatoma derived cell line hepg2/product/ATCC
    Average 99 stars, based on 1 article reviews
    human hepatoma derived cell line hepg2 - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    99
    ATCC human hepatoma cell line hepg2 cells
    <t>HepG2</t> cells were transfected with 1nM Control mimic (Ctrl) or miR-210 mimic, then treated with fatty acids and cultured under hypoxic conditions. miR-210 expression ( A ), intracellular triglyceride levels ( B ), and gene expression ( C ) were analyzed. ( D ) CIDEC protein expression was assessed by Western blotting. Quantification is shown in the histogram. (E-F) RNA pull-down assays. (E) Schematic illustration of the RNA pull-down experiment. Sequences of biotin-conjugated miR-210 mimic and the CIDEC mRNA 3’UTR region containing miR-210 binding site are shown. HepG2 cells were transfected with biotin-conjugated miR-210 mimic or control mimic, treated with fatty acids under hypoxic conditions. Streptavidin-coated magnetic beads captured biotin-labeled miR-210 and associated mRNAs via its binding sites in 3’ UTR. (F) qPCR analysis of miR-210, CIDEC and ACTB (negative control) mRNAs in the pull-down fraction. (G–H) Dual-luciferase reporter assay in HepG2 cells co-transfected with WT (G) or mutant (Mut, H ) CIDEC 3′UTR luciferase reporter and control or miR-210 mimic, followed by exposure to fatty acids and hypoxia. (I) Western blot validation of FLAG-CIDEC-GFP and FLAG-GFP expression using anti-CIDEC and anti-FLAG antibodies. α-tubulin was used as loading control. (J) Representative confocal images demonstrating FLAG-GFP or FLAG-CIDEC-GFP expression (green), lipid droplets stained with Oil Red O (red), and nuclei stained with DAPI (blue). Scale bar: 10 μm. (K) Quantification of intracellular triglyceride levels under the indicated conditions. Data are presented as mean ± SEM; n=3-6. Statistical significance was determined by unpaired Student’s t-test test or Mann-Whitney U test. * p < 0.05; ** p < 0.01. ns: no significant difference.
    Human Hepatoma Cell Line Hepg2 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human hepatoma cell line hepg2 cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    human hepatoma cell line hepg2 cells - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    Image Search Results


    PPA-mediated reduction in lipid accumulation involves enhanced lipolysis and fatty acid oxidation in HepG2 cells. ( A ) Following 24 h incubation with 500 μM oleic acid (OA) or bovine serum albumin (BSA), HepG2 cells were exposed to PPA at concentrations of 0, 0.5, 0.75, 1, or 5 mM for an additional 48 h. Cell viability was determined via the CCK-8 assay. ( B ) Oil Red O staining images illustrate lipid droplets (scale bar = 200 μm). ( C ) Quantitative assessment of lipid content from Oil Red O staining. ( D ) Fluorescence images of BODIPY 493/503-stained lipid droplets (scale bar = 25 μm). ( E ) Mean fluorescence intensity quantification of BODIPY 493/503 staining. ( F , G ) Western blot analysis for detecting phosphorylated ATGL (p-ATGL) and total ATGL (t-ATGL). ( H , I ) CPT1A expression levels were examined by Western blotting. Colors represent the following groups: control (gray), OA alone (green), OA plus PPA at the indicated concentrations (orange). Group labels are displayed on the x-axis. Data represent mean ± SEM; n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns represents no significant difference.

    Journal: International Journal of Molecular Sciences

    Article Title: Gut Microbiota-Derived Propionic Acid Mediates ApoA-I-Induced Amelioration of MASLD via Activation of GPR43–Ca 2+ –CAMKII–ATGL Hepatic Lipolysis

    doi: 10.3390/ijms27010468

    Figure Lengend Snippet: PPA-mediated reduction in lipid accumulation involves enhanced lipolysis and fatty acid oxidation in HepG2 cells. ( A ) Following 24 h incubation with 500 μM oleic acid (OA) or bovine serum albumin (BSA), HepG2 cells were exposed to PPA at concentrations of 0, 0.5, 0.75, 1, or 5 mM for an additional 48 h. Cell viability was determined via the CCK-8 assay. ( B ) Oil Red O staining images illustrate lipid droplets (scale bar = 200 μm). ( C ) Quantitative assessment of lipid content from Oil Red O staining. ( D ) Fluorescence images of BODIPY 493/503-stained lipid droplets (scale bar = 25 μm). ( E ) Mean fluorescence intensity quantification of BODIPY 493/503 staining. ( F , G ) Western blot analysis for detecting phosphorylated ATGL (p-ATGL) and total ATGL (t-ATGL). ( H , I ) CPT1A expression levels were examined by Western blotting. Colors represent the following groups: control (gray), OA alone (green), OA plus PPA at the indicated concentrations (orange). Group labels are displayed on the x-axis. Data represent mean ± SEM; n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns represents no significant difference.

    Article Snippet: The HepG2 human hepatoma cell line (obtained from ATCC) was maintained under standard conditions at 37 °C with 5% CO 2 .

    Techniques: Incubation, CCK-8 Assay, Staining, Fluorescence, Western Blot, Expressing, Control

    PPA promotes activation of CAMKII and ATGL in a Ca 2 ⁺-dependent manner in OA-overloaded HepG2 cells. ( A ) After a 24 h incubation with 500 μM OA or BSA, HepG2 cells were exposed to 0.5 or 1 mM PPA for 48 h. Cytosolic Ca 2+ levels were measured. ( B , C ) Western blot analysis for detecting phosphorylated CAMKII (p-CAMKII) and total CAMKII (t-CAMKII). ( D – F ) HepG2 cells pretreated with OA or BSA for 24 h were co-incubated with PPA (0.5 or 1 mM) in the presence or absence of 10 μM BAPTA. Protein extracts were then assessed for p-CAMKII, t-CAMKII, p-ATGL, and t-ATGL via Western blotting. Groups are denoted by color: control (gray), OA alone (green), OA + PPA (orange), and OA + PPA + BAPTA (lime green). PPA concentrations are as indicated. All groups are labeled on the x-axis. Data are expressed as mean ± SEM; n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns represents no significant difference.

    Journal: International Journal of Molecular Sciences

    Article Title: Gut Microbiota-Derived Propionic Acid Mediates ApoA-I-Induced Amelioration of MASLD via Activation of GPR43–Ca 2+ –CAMKII–ATGL Hepatic Lipolysis

    doi: 10.3390/ijms27010468

    Figure Lengend Snippet: PPA promotes activation of CAMKII and ATGL in a Ca 2 ⁺-dependent manner in OA-overloaded HepG2 cells. ( A ) After a 24 h incubation with 500 μM OA or BSA, HepG2 cells were exposed to 0.5 or 1 mM PPA for 48 h. Cytosolic Ca 2+ levels were measured. ( B , C ) Western blot analysis for detecting phosphorylated CAMKII (p-CAMKII) and total CAMKII (t-CAMKII). ( D – F ) HepG2 cells pretreated with OA or BSA for 24 h were co-incubated with PPA (0.5 or 1 mM) in the presence or absence of 10 μM BAPTA. Protein extracts were then assessed for p-CAMKII, t-CAMKII, p-ATGL, and t-ATGL via Western blotting. Groups are denoted by color: control (gray), OA alone (green), OA + PPA (orange), and OA + PPA + BAPTA (lime green). PPA concentrations are as indicated. All groups are labeled on the x-axis. Data are expressed as mean ± SEM; n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns represents no significant difference.

    Article Snippet: The HepG2 human hepatoma cell line (obtained from ATCC) was maintained under standard conditions at 37 °C with 5% CO 2 .

    Techniques: Activation Assay, Incubation, Western Blot, Control, Labeling

    GPR43 is involved in PPA-induced activation of the Ca 2 ⁺–CAMKII–ATGL pathway in HepG2 cells. ( A ) After a 24 h incubation with 500 μM OA or BSA, HepG2 cells were exposed to 0.5 or 1 mM PPA with or without 1 μM GLPG0974, after which cytosolic Ca 2 ⁺ levels were measured. ( B – D ) Protein extracts were assessed for p-CAMKII, t-CAMKII, p-ATGL and t-ATGL via Western blotting. Groups are denoted by color: control (gray), OA alone (green), OA + PPA (orange), and OA + PPA + GLPG0974 (lime green). PPA concentrations are as indicated. All groups are labeled on the x-axis. Data represent mean ± SEM; n = 3. * p < 0.05, ** p < 0.01; ns represents no significant difference.

    Journal: International Journal of Molecular Sciences

    Article Title: Gut Microbiota-Derived Propionic Acid Mediates ApoA-I-Induced Amelioration of MASLD via Activation of GPR43–Ca 2+ –CAMKII–ATGL Hepatic Lipolysis

    doi: 10.3390/ijms27010468

    Figure Lengend Snippet: GPR43 is involved in PPA-induced activation of the Ca 2 ⁺–CAMKII–ATGL pathway in HepG2 cells. ( A ) After a 24 h incubation with 500 μM OA or BSA, HepG2 cells were exposed to 0.5 or 1 mM PPA with or without 1 μM GLPG0974, after which cytosolic Ca 2 ⁺ levels were measured. ( B – D ) Protein extracts were assessed for p-CAMKII, t-CAMKII, p-ATGL and t-ATGL via Western blotting. Groups are denoted by color: control (gray), OA alone (green), OA + PPA (orange), and OA + PPA + GLPG0974 (lime green). PPA concentrations are as indicated. All groups are labeled on the x-axis. Data represent mean ± SEM; n = 3. * p < 0.05, ** p < 0.01; ns represents no significant difference.

    Article Snippet: The HepG2 human hepatoma cell line (obtained from ATCC) was maintained under standard conditions at 37 °C with 5% CO 2 .

    Techniques: Activation Assay, Incubation, Western Blot, Control, Labeling

    ( A ) Top, the results of ChIP-seq with anti-FoxO1 antibody in livers of unfed mice obtained from ChIP-Atlas (ID: GSM3381273); bottom, simplified representation of the structure of the full fragment, fragment 1, fragment 2, fragment 3, and the subdivisions of fragment 1 i.e. small fragment 1A and small fragment 1B. ( B and C ) Enhancer analysis of FoxO1 and FoxO3a on Ass1 enhancer and its fragments. FoxO1 and FoxO3a expression plasmids were co-transfected with the indicated Ass1 enhancer firefly luciferase reporter plasmids in HepG2 cells. ( D and E ) Electrophoretic mobility shift assay (EMSA) using radiolabeled probe for ( D ) the two JASPAR predicted FoxO binding sites (Figure S5) in the smallest fragment 1A from the Ass1 enhancer and FoxO binding site in the promoter of Pck1 as a positive control; ( E ) the wild-type (WT) and mutant (Mut) predicted FoxO binding site1 incubated with GST and GST-FoxO recombinant proteins. BS, binding site; WT, wild-type; Mut, mutant. ( F ) Enhancer analysis of FoxO1 and FoxO3a on mutant Ass1 enhancer and its fragments. FoxO1 and FoxO3a expression plasmids were co-transfected with the indicated Ass1 enhancer firefly luciferase reporter plasmids in HepG2 cells. All values are presented as the mean with error bars representing the SEM. Datasets were assessed by Student’s t -test for unpaired samples. The differences were considered to be significant if P < 0.05 (* P < 0.05 and ** P <0.01).

    Journal: bioRxiv

    Article Title: FoxO transcription factors couple the urea cycle and gluconeogenesis by controlling Ass1

    doi: 10.64898/2025.12.22.695746

    Figure Lengend Snippet: ( A ) Top, the results of ChIP-seq with anti-FoxO1 antibody in livers of unfed mice obtained from ChIP-Atlas (ID: GSM3381273); bottom, simplified representation of the structure of the full fragment, fragment 1, fragment 2, fragment 3, and the subdivisions of fragment 1 i.e. small fragment 1A and small fragment 1B. ( B and C ) Enhancer analysis of FoxO1 and FoxO3a on Ass1 enhancer and its fragments. FoxO1 and FoxO3a expression plasmids were co-transfected with the indicated Ass1 enhancer firefly luciferase reporter plasmids in HepG2 cells. ( D and E ) Electrophoretic mobility shift assay (EMSA) using radiolabeled probe for ( D ) the two JASPAR predicted FoxO binding sites (Figure S5) in the smallest fragment 1A from the Ass1 enhancer and FoxO binding site in the promoter of Pck1 as a positive control; ( E ) the wild-type (WT) and mutant (Mut) predicted FoxO binding site1 incubated with GST and GST-FoxO recombinant proteins. BS, binding site; WT, wild-type; Mut, mutant. ( F ) Enhancer analysis of FoxO1 and FoxO3a on mutant Ass1 enhancer and its fragments. FoxO1 and FoxO3a expression plasmids were co-transfected with the indicated Ass1 enhancer firefly luciferase reporter plasmids in HepG2 cells. All values are presented as the mean with error bars representing the SEM. Datasets were assessed by Student’s t -test for unpaired samples. The differences were considered to be significant if P < 0.05 (* P < 0.05 and ** P <0.01).

    Article Snippet: HEK293 human embryonic kidney cells (RRID:CVCL_0045) and HepG2 human hepatoma cells (RRID: CVCL_0027) were distributed from ATCC (American Type Culture Collection, Manassas, VA, USA), and cultured in DMEM containing 25 mM glucose, 100 U/mL penicillin, and 100 μg/mL streptomycin sulfate supplemented with 10% FBS.

    Techniques: ChIP-sequencing, Expressing, Transfection, Luciferase, Electrophoretic Mobility Shift Assay, Binding Assay, Positive Control, Mutagenesis, Incubation, Recombinant, IF-P

    HepG2 cells were transfected with 1nM Control mimic (Ctrl) or miR-210 mimic, then treated with fatty acids and cultured under hypoxic conditions. miR-210 expression ( A ), intracellular triglyceride levels ( B ), and gene expression ( C ) were analyzed. ( D ) CIDEC protein expression was assessed by Western blotting. Quantification is shown in the histogram. (E-F) RNA pull-down assays. (E) Schematic illustration of the RNA pull-down experiment. Sequences of biotin-conjugated miR-210 mimic and the CIDEC mRNA 3’UTR region containing miR-210 binding site are shown. HepG2 cells were transfected with biotin-conjugated miR-210 mimic or control mimic, treated with fatty acids under hypoxic conditions. Streptavidin-coated magnetic beads captured biotin-labeled miR-210 and associated mRNAs via its binding sites in 3’ UTR. (F) qPCR analysis of miR-210, CIDEC and ACTB (negative control) mRNAs in the pull-down fraction. (G–H) Dual-luciferase reporter assay in HepG2 cells co-transfected with WT (G) or mutant (Mut, H ) CIDEC 3′UTR luciferase reporter and control or miR-210 mimic, followed by exposure to fatty acids and hypoxia. (I) Western blot validation of FLAG-CIDEC-GFP and FLAG-GFP expression using anti-CIDEC and anti-FLAG antibodies. α-tubulin was used as loading control. (J) Representative confocal images demonstrating FLAG-GFP or FLAG-CIDEC-GFP expression (green), lipid droplets stained with Oil Red O (red), and nuclei stained with DAPI (blue). Scale bar: 10 μm. (K) Quantification of intracellular triglyceride levels under the indicated conditions. Data are presented as mean ± SEM; n=3-6. Statistical significance was determined by unpaired Student’s t-test test or Mann-Whitney U test. * p < 0.05; ** p < 0.01. ns: no significant difference.

    Journal: bioRxiv

    Article Title: HypoxamicroRNA-210 protects against hepatic steatosis by inhibiting CIDEC expression

    doi: 10.64898/2025.12.19.695309

    Figure Lengend Snippet: HepG2 cells were transfected with 1nM Control mimic (Ctrl) or miR-210 mimic, then treated with fatty acids and cultured under hypoxic conditions. miR-210 expression ( A ), intracellular triglyceride levels ( B ), and gene expression ( C ) were analyzed. ( D ) CIDEC protein expression was assessed by Western blotting. Quantification is shown in the histogram. (E-F) RNA pull-down assays. (E) Schematic illustration of the RNA pull-down experiment. Sequences of biotin-conjugated miR-210 mimic and the CIDEC mRNA 3’UTR region containing miR-210 binding site are shown. HepG2 cells were transfected with biotin-conjugated miR-210 mimic or control mimic, treated with fatty acids under hypoxic conditions. Streptavidin-coated magnetic beads captured biotin-labeled miR-210 and associated mRNAs via its binding sites in 3’ UTR. (F) qPCR analysis of miR-210, CIDEC and ACTB (negative control) mRNAs in the pull-down fraction. (G–H) Dual-luciferase reporter assay in HepG2 cells co-transfected with WT (G) or mutant (Mut, H ) CIDEC 3′UTR luciferase reporter and control or miR-210 mimic, followed by exposure to fatty acids and hypoxia. (I) Western blot validation of FLAG-CIDEC-GFP and FLAG-GFP expression using anti-CIDEC and anti-FLAG antibodies. α-tubulin was used as loading control. (J) Representative confocal images demonstrating FLAG-GFP or FLAG-CIDEC-GFP expression (green), lipid droplets stained with Oil Red O (red), and nuclei stained with DAPI (blue). Scale bar: 10 μm. (K) Quantification of intracellular triglyceride levels under the indicated conditions. Data are presented as mean ± SEM; n=3-6. Statistical significance was determined by unpaired Student’s t-test test or Mann-Whitney U test. * p < 0.05; ** p < 0.01. ns: no significant difference.

    Article Snippet: Human hepatoma cell line HepG2 cells (ATCC, USA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM, 4.5 g/L glucose) supplemented with 100 U/ml penicillin, 100 μg/mL streptomycin, and 10% FBS (ThermoFisher Scientific).

    Techniques: Transfection, Control, Cell Culture, Expressing, Gene Expression, Western Blot, Binding Assay, Magnetic Beads, Labeling, Negative Control, Luciferase, Reporter Assay, Mutagenesis, Biomarker Discovery, Staining, MANN-WHITNEY